PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays oxygen dependency and improves survival in both idiopathic pulmonary fibrosis ...

Ensem Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ETX-636, a Potential Best-In-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader - ETX–636 is ...

This important study looks into the effect of exogenous CoA on the response of TLR4-activated macrophages. Specifically, CoA enhances the LPS response by examining metabolomics, 13C tracing, and ...

VIDEO: JAK inhibitor adherence key to getting ‘appropriate balance between risk and benefit’Editor’s note: This is an automatically generated transcript. Please notify [email protected] if ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through ...

PDE3 inhibitors are already in clinical use for treating heart failure, thrombosis, asthma, and other conditions, but their potential in promoting bone outgrowth by enhancing CNP signaling ...

PDE4 Inhibitors. Roflumilast: Roflumilast is the only oral phosphodiesterase-4 (PDE4) inhibitor currently available to treat COPD by reducing the risk of acute exacerbations.